Trial Profile
LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Fetal alcohol syndrome; Huntington's disease; Social phobia
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 01 Nov 2016 Primary endpoint (Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)]) has been met, according to results published in the Clinical Drug Investigation.
- 01 Nov 2016 Primary endpoint (Maximum Observed Plasma Concentration (Cmax)) has been met, according to results published in the Clinical Drug Investigation.
- 01 Nov 2016 Results published in the Clinical Drug Investigation